Bellicum Pharmaceuticals Lands $55,000,000 Series C Financing

  • Feed Type
  • Date
    8/27/2014
  • Company Name
    Bellicum Pharmaceuticals
  • Mailing Address
    2130 West Holcombe Boulevard Houston, TX 77030 USA
  • Company Description
    Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum utilize’s precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.
  • Website
    http://www.bellicum.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T cell and cancer vaccine product candidates in a variety of blood and solid tumor cancers, and in nonmalignant genetic diseases.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.